LncRNA TTN-AS1 sponges miR-376a-3p to promote colorectal cancer progression via upregulating KLF15
In conclusions, TTN-AS1 promoted CRC proliferation and invasion through miR-376a-3p/KLF15 axis. Our findings suggested that TTN-AS1 might be a potential therapeutic target in CRC treatment.
Publication date: Available online 12 November 2019Source: Life SciencesAuthor(s): Jiaping Pei, Wen Xiao, Danyan Zhu, Xiaowei Ji, Liping Shi, Xiaozhao DengAbstractAimsThis work is to explore the expression, function and mechanism of long non-coding RNA (lncRNA) DSCAM-AS1 in colorectal cancer (CRC).Materials and MethodsPaired CRC tissues/adjacent tissues were collected to examine their expression levels of DSCAM-AS1, miR-144-5p and CDKL1 by qRT-PCR; DSCAM-AS1 shRNA was transfected into HCT-116 and SW480 cells to establish cell models, whose proliferation was detected by CCK-8 and plate colony formation assays. Transwell ass...
Abstract14 new naphthoquinones were prepared and tested against human cancer cell lines PC-3 (prostate), HCT-116 (colon carcinoma), SNB-19 (glioblastoma), HL-60 (leukemia) and MCF-7 (breast), and a nontumor cell line L929 (murine fibroblasts) to determine cytotoxicity with the MTT assay. 8-OH- β-lapachones (14a,14c,14d) presented best results, showing low IC50 values and high selectivity for HCT-116 and HL-60 tumor cells.
Authors: Arora R, Kisiel M, MacColl C Abstract Mutations in EGFR have been implicated in the pathogenesis of various types of cancer, and therefore antibody therapy directed against the epidermal growth factor receptor (egfr) is increasingly being used in the management of various cancers. Currently, anti-egfr antibodies are used mainly in the management of cancers of the head and neck and metastatic colorectal cancers. Because of this increasing use, we would like to inform the oncology community in North America of a rare, but life-threatening, toxicity associated with anti-egfr antibody therapy. Although cases i...
Authors: Hyde AJ, Nassabein R, AlShareef A, Armstrong D, Babak S, Berry S, Bossé D, Chen E, Colwell B, Essery C, Goel R, Goodwin R, Gray S, Hammad N, Jeyakuymar A, Jonker D, Karanicolas P, Lamond N, Letourneau R, Michael J, Patil N, Powell E, Ramjeesingh R, Saliba W, Singh R, Snow S, Stuckless T, Tadros S, Tehfé M, Thana M, Thirlwell M, Vickers M, Virik K, Welch S, Asmis T Abstract The annual Eastern Canadian Gastrointestinal Cancer Consensus Conference was held in Halifax, Nova Scotia, 20-22 September 2018. Experts in radiation oncology, medical oncology, surgical oncology, and pathology who are invo...
Conclusions: Selective use of an egfri based on ptl was more cost-effective than unselected use of those agents; however, based on traditional wtp thresholds, it was still not cost-effective. While awaiting the elucidation of more precise predictive biomarkers that might improve cost-effectiveness, the price of egfris could be reduced to meet the wtp threshold. PMID: 31708653 [PubMed - in process]
Conclusions: In advanced mcrc, ftd/tpi is a well-tolerated therapy. The large number of patients enrolled in the access programs within a short period of time is reflective of major clinical need in this area, with many patients being eligible and interested in pursuing treatment in the refractory setting. PMID: 31708650 [PubMed - in process]
Condition: Colorectal Neoplasm Intervention: Genetic: Multi-Cancer Cancer Panel Sponsor: University of Colorado, Denver Recruiting
Conditions: Patient Empowerment; Patient Activation; Self Care; Cancer of Colon; Cancer of Rectum Intervention: Behavioral: Educational nursing intervention on nutrition intake related chemotherapy induced side-effects' self-care among the patients with colorectal cancer Sponsors: University of Turku; Helsinki University Central Hospital Recruiting
Conditions: Colorectal Cancer; Liver Metastases; Colorectal Liver Metastases Interventions: Procedure: Liver transplantation Ltx; Other: Best alternative care Sponsor: Vastra Gotaland Region Not yet recruiting
ConclusionsAn 11-point modified frailty index as measured in NSQIP correlates with readmissions after colorectal resection in patients with colon and rectal cancer.